Fatima Faiza, Fatima Mahnoor, Raza Ahmed, Ahmad Bilal, Akilimali Aymar
Services Institute of Medical Sciences, Lahore, Pakistan.
King Edward Medical University, Lahore, Pakistan.
Ann Med Surg (Lond). 2025 Apr 4;87(5):3050-3051. doi: 10.1097/MS9.0000000000003260. eCollection 2025 May.
Alcohol-induced liver disease, encompassing steatosis, hepatitis, cirrhosis, and liver failure, is a significant global health burden, affecting 10-35% of individuals with alcohol use disorder. Alcoholic hepatitis, characterized by hepatocyte inflammation due to chronic alcohol consumption, arises from toxic intermediates produced during alcohol metabolism. These intermediates disrupt cellular function, trigger immune responses, and promote fibrosis, leading to cirrhosis and liver failure. Despite current treatments like corticosteroids and liver transplantation, which alleviate symptoms but fail to reverse cellular damage, the rising prevalence of alcoholic hepatitis underscores the urgent need for innovative therapies. Larsucosterol, a novel epigenetic modulator, has emerged as a promising candidate. By inhibiting DNA methyltransferase, larsucosterol reduces DNA hypermethylation and modulates genes involved in inflammation, lipid metabolism, and cell survival, thereby mitigating liver damage. Early-phase clinical trials, including a phase 2a study, demonstrated its safety, tolerability, and improved biochemical parameters in patients. However, the phase 2b AHFIRM trial did not achieve its primary endpoint, though a lower mortality rate in the 30 mg group suggests potential benefits requiring further investigation. Larsucosterol's immunomodulatory and anti-inflammatory properties offer advantages over corticosteroids, particularly in patients unresponsive to standard therapies. Despite its promise, limitations such as the need for larger, more diverse trials, long-term safety data, and exploration of combination therapies remain. In conclusion, larsucosterol represents a groundbreaking approach to treating alcoholic hepatitis, but extensive research is essential to fully establish its therapeutic potential and address existing gaps in knowledge.
酒精性肝病包括脂肪变性、肝炎、肝硬化和肝衰竭，是一项重大的全球健康负担，影响着10%-35%的酒精使用障碍患者。酒精性肝炎的特征是由于长期饮酒导致肝细胞炎症，它源于酒精代谢过程中产生的有毒中间体。这些中间体破坏细胞功能，引发免疫反应，并促进纤维化，导致肝硬化和肝衰竭。尽管目前有皮质类固醇和肝移植等治疗方法，这些方法可以缓解症状，但无法逆转细胞损伤，但酒精性肝炎患病率的上升凸显了对创新疗法的迫切需求。新型表观遗传调节剂拉苏可醇已成为一个有前景的候选药物。通过抑制DNA甲基转移酶，拉苏可醇可减少DNA高甲基化，并调节参与炎症、脂质代谢和细胞存活的基因，从而减轻肝损伤。包括2a期研究在内的早期临床试验证明了其在患者中的安全性、耐受性和改善的生化指标。然而，2b期AHFIRM试验没有达到其主要终点，尽管30毫克组的死亡率较低表明可能存在益处，需要进一步研究。拉苏可醇的免疫调节和抗炎特性优于皮质类固醇，特别是在对标准疗法无反应的患者中。尽管它有前景，但仍存在一些局限性，如需要进行更大规模、更多样化的试验、长期安全性数据以及探索联合疗法。总之，拉苏可醇代表了一种治疗酒精性肝炎的开创性方法，但全面确立其治疗潜力并填补现有知识空白，广泛的研究至关重要。
